MHLW Committee Endorses QVA149's Approval To Treat COPD

On August 26, Sosei reported that the Drug Committee of Ministry of Health, Labour and Welfare (MHLW) in Japan has endorsed approval of once daily QVA149 (glycopyrronium bromide+indacaterol), developed by Novartis, as a treatment to relieve symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD) in Japan. The Japanese MHLW is expected to follow with

approval in due course.

The product combines two bronchodilators: glycopyrronium, a long-acting muscarinic antagonist; and indacaterol, a long-acting beta2-adrenergic agonist. In July, the EMA's CHMP adopted a positive opinion for the approval of QVA149 in Europe under the brandname, Ultibro Breezhaler. Ultibro and Breezhaler are registered trademarks of Novartis.

MHLW Committee Endorses QVA149's Approval To Treat COPD

On August 26, Sosei reported that the Drug Committee of Ministry of Health, Labour and Welfare (MHLW) in Japan has endorsed approval of once daily QVA149 (glycopyrronium bromide+indacaterol), developed by Novartis, as a treatment to relieve symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD) in Japan. The Japanese MHLW is expected to follow with

approval in due course.

The product combines two bronchodilators: glycopyrronium, a long-acting muscarinic antagonist; and indacaterol, a long-acting beta2-adrenergic agonist. In July, the EMA's CHMP adopted a positive opinion for the approval of QVA149 in Europe under the brandname, Ultibro Breezhaler. Ultibro and Breezhaler are registered trademarks of Novartis.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.